Skip to main content

Melian Agustin's Form 4 filing

Kalaris Therapeutics, Inc. (KLRS) · filed Oct 5, 2021

Accession no.
0000899243-21-039356
Filed
Oct 5, 2021
Trade date
Oct 4, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $446.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Melian AgustinCIK 0001818064Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 4, 2021Common StockSSaleDisposed−10,678$23.29F2−$248,690.62461,540Direct
Oct 4, 2021Common StockSSaleDisposed−4,711$24.23F3−$114,147.53456,829Direct
Oct 4, 2021Common StockSSaleDisposed−2,967$25.41F4−$75,391.47453,862Direct
Oct 4, 2021Common StockSSaleDisposed−333$26.02F5−$8,664.66453,529Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)